Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 54

Results For "FY"

2300 News Found

Vinati Organics consolidated Q2FY23 PAT up 43% at Rs. 116 Cr
News | November 08, 2022

Vinati Organics consolidated Q2FY23 PAT up 43% at Rs. 116 Cr

The company posted net profit of Rs.81.33 crores for the quarter ended September 30, 2021.


Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%
News | November 07, 2022

Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%

H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY


Tatva Chintan Q2 FY23 revenue down 27%; Net profit down 78%
News | November 07, 2022

Tatva Chintan Q2 FY23 revenue down 27%; Net profit down 78%

Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%


Balaxi Pharmaceuticals delivers strong growth in Q2 FY23
News | November 07, 2022

Balaxi Pharmaceuticals delivers strong growth in Q2 FY23

Revenue is up 23% whereas Profit After Tax expands 29% for the company


GMM Pfaudler Q2FY23 consolidated profit up at Rs. 64.98 Cr
News | November 04, 2022

GMM Pfaudler Q2FY23 consolidated profit up at Rs. 64.98 Cr

The company has reported total income of Rs. 799.52 crores during the period ended September 30, 2022


Hester Biosciences Q2 FY23 consolidated profit up at Rs. 6.94 Cr
News | November 04, 2022

Hester Biosciences Q2 FY23 consolidated profit up at Rs. 6.94 Cr

The company has reported total income of Rs. 77.60 crores during the period ended September 30, 2022


Jubilant Ingrevia to invest Rs. 2,050 crore during FY 22-25
News | November 01, 2022

Jubilant Ingrevia to invest Rs. 2,050 crore during FY 22-25

Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side


Granules India plans H2 FY 2022-23 R&D spend in Rs. 80-90 Cr
News | October 30, 2022

Granules India plans H2 FY 2022-23 R&D spend in Rs. 80-90 Cr

The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track


Vimta Labs posts consolidated PAT of Rs. 13.21 crores in Q2FY23
News | October 28, 2022

Vimta Labs posts consolidated PAT of Rs. 13.21 crores in Q2FY23

The company has posted net profit of Rs. 13.21 crores for the period ended September 30, 2022


Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr
News | October 27, 2022

Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr

Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr